VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$4.72 USD
-0.11 (-2.28%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $4.74 +0.02 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for VistaGen Therapeutics, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -59.25 | -47.76 | -17.93 | -20.77 |
Depreciation/Amortization & Depletion | NA | 0.13 | 0.15 | 0.12 | 0.12 |
Net Change from Assets/Liabilities | NA | 2.46 | -1.24 | 3.39 | 0.09 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 6.94 | 3.59 | 2.35 | 4.81 |
Net Cash From Operating Activities | NA | -49.72 | -45.26 | -12.07 | -15.76 |
Property & Equipment | NA | -0.21 | -0.20 | -0.28 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | -0.53 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.74 | -0.20 | -0.28 | 0.00 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -0.01 | 10.49 | 114.48 | 4.01 |
Issuance (Repayment) of Debt | NA | -1.04 | 0.00 | -0.38 | -0.30 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.30 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -1.04 | 10.48 | 114.10 | 4.01 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -51.50 | -34.97 | 101.75 | -11.75 |
Cash at Beginning of Period | NA | 68.14 | 103.11 | 1.36 | 13.10 |
Cash at End of Period | NA | 16.64 | 68.14 | 103.11 | 1.36 |
Diluted Net EPS | NA | -8.51 | -7.51 | -14.71 | -15.02 |
Fiscal Year End for VistaGen Therapeutics, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -19.84 | -13.49 | -6.90 | -59.25 |
Depreciation/Amortization & Depletion | NA | 0.09 | 0.06 | 0.03 | 0.13 |
Net Change from Assets/Liabilities | NA | -0.50 | -1.79 | -1.58 | 2.46 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 1.63 | 1.13 | 0.56 | 6.94 |
Net Cash From Operating Activities | NA | -18.62 | -14.08 | -7.89 | -49.72 |
Property & Equipment | NA | -0.03 | 0.00 | 0.00 | -0.21 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | -0.53 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.03 | 0.00 | 0.00 | -0.74 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 129.56 | 36.04 | 1.08 | -0.01 |
Issuance (Repayment) of Debt | NA | -0.99 | -0.99 | -0.20 | -1.04 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 128.57 | 35.05 | 0.88 | -1.04 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 109.92 | 20.97 | -7.02 | -51.50 |
Cash at Beginning of Period | NA | 16.64 | 16.64 | 16.64 | 68.14 |
Cash at End of Period | NA | 126.56 | 37.61 | 9.62 | 16.64 |
Diluted Net EPS | NA | -0.22 | -0.66 | -0.94 | -1.60 |